Exelixis Announces U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differen
Go back to Exelixis Announces U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differen| Exelixis, Inc. (NASDAQ: EXEL) | Delayed: 57.12 -1.24 (2.12%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $58.36 | 52 Week High | $17.00 | |||
| Open | $58.61 | 52 Week Low | $3.55 | |||
| Day High | $58.81 | P/E | N/A | |||
| Day Low | $56.90 | EPS | $-1.33 | |||
| Volume | 921,404 | |||||
